Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.

Engelhardt JJ, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, Egeblad M, Krummel MF.

Cancer Cell. 2012 Mar 20;21(3):402-17. doi: 10.1016/j.ccr.2012.01.008.

2.
3.

Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.

McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BW.

Eur J Immunol. 2015 Jan;45(1):49-59. doi: 10.1002/eji.201444722. Epub 2014 Dec 15.

4.

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.

Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ.

Cancer Immunol Immunother. 2014 May;63(5):437-48. doi: 10.1007/s00262-014-1525-z. Epub 2014 Feb 15.

PMID:
24531387
5.
6.

Tumor antigen cross-presentation and the dendritic cell: where it all begins?

McDonnell AM, Robinson BW, Currie AJ.

Clin Dev Immunol. 2010;2010:539519. doi: 10.1155/2010/539519. Epub 2010 Oct 13.

8.

Tumor antigen presentation by dendritic cells.

Petersen TR, Dickgreber N, Hermans IF.

Crit Rev Immunol. 2010;30(4):345-86. Review.

PMID:
20666707
9.

Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.

Rolinski J, Hus I.

J Immunotoxicol. 2014 Oct;11(4):311-8. doi: 10.3109/1547691X.2013.865094. Epub 2014 Feb 4. Review.

PMID:
24495309
11.

Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.

Kass R, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD.

Breast Cancer Res Treat. 2003 Aug;80(3):275-85.

PMID:
14503800
12.

The emerging understanding of myeloid cells as partners and targets in tumor rejection.

Broz ML, Krummel MF.

Cancer Immunol Res. 2015 Apr;3(4):313-9. doi: 10.1158/2326-6066.CIR-15-0041. Review.

13.

Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses.

Zhou Y, McEarchern JA, Howard E, Pestano G, Salgaller ML, Bosch ML.

Cancer Immunol Immunother. 2003 Jul;52(7):413-22. Epub 2003 Feb 15.

PMID:
12835918
14.

Cell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells.

Zanetti M.

Ann N Y Acad Sci. 2013 May;1284:6-11. doi: 10.1111/nyas.12103. Review.

PMID:
23651187
15.

Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells.

Manches O, Lui G, Molens JP, Sotto JJ, Chaperot L, Plumas J.

Cytotherapy. 2008;10(6):642-9. doi: 10.1080/14653240802317647.

16.

Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation.

Chhabra A, Mehrotra S, Chakraborty NG, Mukherji B, Dorsky DI.

Eur J Immunol. 2004 Oct;34(10):2824-33.

17.

Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients.

Domschke C, Schuetz F, Sommerfeldt N, Rom J, Scharf A, Sohn C, Schneeweiss A, Beckhove P.

Cancer Immunol Immunother. 2010 Mar;59(3):479-86. doi: 10.1007/s00262-009-0801-9. Epub 2009 Dec 2.

PMID:
19957084
18.
19.

Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

J Immunol. 2012 Jun 15;188(12):6389-98. doi: 10.4049/jimmunol.1103019. Epub 2012 May 14. Erratum in: J Immunol. 2014 Aug 1;193(3):1513.

20.

Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.

Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, Ronchese F.

Cancer Immunol Immunother. 2008 Nov;57(11):1665-73. doi: 10.1007/s00262-008-0487-4. Epub 2008 Mar 1.

PMID:
18311487

Supplemental Content

Support Center